Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 293 participants.

Also called NCT01582230

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 293 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01582230
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China, Philippines, Singapore, Thailand (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01582230. Randomized; double masking; primary purpose treatment. Start 2012-04 (registry gives no type); primary completion 2013-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Vildagliptin
Intervention (Drug)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01582230
Content hash
f4bef4052d38eae84f6a803a07f20204b859de6176dd0bb7f64a89d2d694cb44